The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma

Takashi Ishida, Shinsuke Iida, Yoshiki Akatsuka, Toshihiko Ishii, Mikinori Miyazaki, Hirokazu Komatsu, Hiroshi Inagaki, Noriko Okada, Teizo Fujita, Kenya Shitara, Shiro Akinaga, Toshitada Takahashi, Atae Utsunomiya, Ryuzo Ueda

研究成果: Article

132 引用 (Scopus)

抜粋

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm with dismal prognosis, and no optimal therapy has been developed. We tested the defucosylated chimeric anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, KM2760, to develop a novel immunotherapy for this refractory tumor. In the presence of peripheral blood mononuclear cells (PBMCs) from healthy adult donors, KM2760 induced CCR4-specific antibody-dependent cellular cytotoxicity (ADCC) against CCR4-positive ATLL cell lines and primary tumor cells obtained from ATLL patients. We next examined the KM2760-induced ADCC against primary ATLL cells in an autologous setting. Antibody-dependent cellular cytotoxicity mediated by autologous effector cells was generally lower than that mediated by allogeneic control effector cells. However, a robust ADCC activity was induced in some cases, which was comparable with that mediated by allogeneic effector cells. It suggests that the ATLL patients' PBMCs retain substantial ADCC-effector function, although the optimal conditions for maximal effect have not yet been determined. In addition, we also found a high expression of FoxP3 mRNA and protein, a hallmark of regulatory T cells, in ATLL cells, indicating the possibility that ATLL cells originated from regulatory T cells. KM2760 reduced FoxP3 mRNA expression in normal PBMCs along with CCR4 mRNA by lysis of CCM4+ T cells in vitro. Our data suggest not only that the CCR4 molecule could be a suitable target for the novel antibody-based therapy for patients with ATLL but also that KM2760 may induce effective tumor immunity by reducing the number of regulatory T cells.

元の言語English
ページ(範囲)7529-7539
ページ数11
ジャーナルClinical Cancer Research
10
発行部数22
DOI
出版物ステータスPublished - 15-12-2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Ishida, T., Iida, S., Akatsuka, Y., Ishii, T., Miyazaki, M., Komatsu, H., Inagaki, H., Okada, N., Fujita, T., Shitara, K., Akinaga, S., Takahashi, T., Utsunomiya, A., & Ueda, R. (2004). The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clinical Cancer Research, 10(22), 7529-7539. https://doi.org/10.1158/1078-0432.CCR-04-0983